Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

PURPOSE: Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of diffuse large B-cell lymphoma (DLBCL). The impact of baseline organ function–based eligibility criteria on this effect...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Khurana, Arushi, Mwangi, Raphael, Nowakowski, Grzegorz S., Habermann, Thomas M., Ansell, Stephen M., LaPlant, Betsy R., Link, Brian K., Cerhan, James R., Maurer, Matthew J., Witzig, Thomas E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wolters Kluwer Health 2021
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274741/
https://ncbi.nlm.nih.gov/pubmed/33529046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01935
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi